Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07713732 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Jul 25, 2026 to Aug 5, 2026 · Eligibility criteria expanded, about 12 words · Site details revised at 3 of 3 sites Show 3 more changesShow less
    • Start date changed from estimate of Jul 25, 2026 to Aug 5, 2026
    • Eligibility criteria expanded, about 12 words
    • Site details revised at 3 of 3 sites
  2. Study sites revised (3)v3 See this version in full on ClinicalTrials.gov ↗
  3. Study title shortened, about 1 wordv2 See this version in full on ClinicalTrials.gov ↗
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Treeline Biosciences, Inc.
4 trials monitored
See all monitored trials
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Sarcoma
951 trials monitored
See 56 trials at risk
Small Cell Lung Cancer
540 trials monitored
See 31 trials at risk
and 1 more disease
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.
Trial Details
NCT Number NCT07713732
Lead Sponsor Treeline Biosciences, Inc.
Conditions Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov